At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
According to Kite, the median turnaround time for Yescarta is expected to be reduced from 16 days to 14 days. The Food and Drug Administration (FDA) has approved a manufacturing process change for ...
A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS ...
Tevogen Bio Holdings Inc. announced that CD8 Technology Services LLC has signed a letter of intent to design a facility that will support Tevogen’s cell therapy manufacturing efforts. CEO Ryan Saadi ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
NETs promote macrophage expression of T-cell chemokines and subsequently facilitate cytotoxic CD8+ T cell infiltration and granzyme B production, which drives kidney fibrosis in obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback